List of Omegaven drug patents

Omegaven is owned by Fresenius Kabi Usa.

Omegaven contains Fish Oil Triglycerides.

Omegaven has a total of 3 drug patents out of which 0 drug patents have expired.

Omegaven was authorised for market use on 27 July, 2018.

Omegaven is available in emulsion;intravenous dosage forms.

Omegaven can be used as treatment of liver disease through nutrition for patients under the age of 12, use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease, treatment of parenteral nutrition-associated cholestasis in patients under the age of 12.

Drug patent challenges can be filed against Omegaven from July, 2022.

The generics of Omegaven are possible to be released after 27 July, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Nov, 2024

(1 year, 8 months from now)

US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(2 years from now)

US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 27, 2023
Orphan Drug Exclusivity (ODE) Jul 27, 2025

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease; Treatment of liver disease through nutrition for patients under the age of 12

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic